Protara Therapeutics TARA
- Market cap
- $142.4M
- PE
- n/m
- a loss over the last year
- Forward PE
- n/m
- not a meaningful number
- Price to sales
- n/m
- one or more of the four quarters through 2026-06-30 missing
- EV/EBIT
- n/m
- a loss over the last year
- Revenue, 12 months
- n/m
- one or more of the four quarters through 2026-06-30 missing
- Net margin
- n/m
- one or more of the four quarters through 2026-06-30 missing
- Free cash flow yield
- n/m
- not a meaningful number
Protara Therapeutics' trailing earnings are negative, so it has no PE.
Charts
Financials
| Income statement | Q3 FY23 | Q4 FY23 | Q1 FY24 | Q2 FY24 | Q3 FY24 | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | |
| R&D | $6.2M+79% | $6.4M+28% | $7.7M+51% | $6.4M−12% | $8.1M+30% | $9.5M+49% | $9.1M+18% | $10.8M+69% | $9.6M+19% | $13.1M+38% | $13.6M+48% | $17M+57% |
| SG&A | $4.5M−1% | $4.7M−7% | $4.1M−11% | $4.3M−13% | $4.3M−5% | $4.8M+3% | $5M+21% | $5.8M+36% | $5.2M+21% | $6M+24% | $6.1M+22% | $6.4M+10% |
| −$10.7M+34% | −$11M−72% | −$11.9M+22% | −$10.7M−12% | −$12.3M+15% | −$14.3M+30% | −$14.1M+19% | −$16.6M+56% | −$14.8M+20% | −$19.1M+33% | −$19.6M+39% | −$23.3M+41% | |
| Interest expense | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Net income | −$9.9M+28% | −$10.2M−74% | −$11.1M+23% | −$9.5M−16% | −$11.2M+14% | −$12.8M+25% | −$11.9M+7% | −$15M+57% | −$13.3M+18% | −$17.3M+36% | −$17.8M+49% | −$21.7M+45% |
| −$0.87+28% | −$0.90 | −$0.97+21% | −$0.45−55% | −$0.50−43% | −$0.47−48% | −$0.29−70% | −$0.35−22% | −$0.31−38% | −$0.38−19% | −$0.31+7% | −$0.36+3% | |
| 11.3M+1% | 11.4M+1% | 11.4M+1% | 21.2M+88% | 22.3M+97% | 27.3M+140% | 40.7M+256% | 42.3M+99% | 42.3M+89% | 46M+69% | 57.5M+41% | 61M+44% |
EPS, diluted: 17 periods, Q4 FY13 to Q4 FY25: quarter's net income to common over its shares, to the cent.
Diluted shares: 7 periods, Q4 FY13 to Q4 FY25: a loss quarter: its basic count, share-days: the 12-month average less the 9-month, weighted by days. Q4 FY19: a loss quarter: its basic count, share-days: the 12-month average over 365 days less the 9-month over 273, the two on one basis (x40). Q4 FY21 and Q4 FY22: share-days: the 12-month average less the 9-month, weighted by days.
From each company's 10-Q and 10-K filings, the newest version of each figure. Quarters are as filed (a fourth quarter is the year less its first nine months), fiscal years as the 10-K prints them, restated where a later 10-K restated them, and balance sheet lines as of the period's end. A quarter whose 10-Q isn't filed yet is from the company's results release. Growth is on the same period a year earlier. A dash is a period with no figure for the line: the filing doesn't print it, or it hasn't been read yet.
Peers
Companies in Healthcare nearest Protara Therapeutics' size, closest first.
| Company | Market cap | PE | Its 10y median PE | Fwd PE | P/S | Revenue growth | Net margin |
|---|---|---|---|---|---|---|---|
| TARAProtara Therapeutics | $142.4M | n/m | n/a | n/m | n/m | n/m | |
| PDEXPro DEX | $184.5M | 15.9× | 16.5× | 2.3× | +13% | 15.1% | |
| PLXProtalix BioTherapeutics | $206.3M | 11.1× | 33.6× | 2.6× | +30% | 23.5% | |
| KEQUKewaunee Scientific | $96.7M | 12.1× | 13.6× | 0.3× | +5% | 3.0% | |
| ICCCImmucell | $95.9M | 132× | 44.1× | 3.1× | +8% | 2.6% | |
| NATRNatures Sunshine Products | $211.5M | 11.9× | 20.2× | 0.4× | +7% | 3.7% | |
| ELMDElectromed | $223.9M | 20.4× | 29.0× | 3.0× | +15% | 15.3% | |
| UTMDUtah Medical Products | $224.6M | 21.5× | 20.9× | 6.2× | −7% | 29.0% | |
| INFUInfuSystem | $275.7M | 33.8× | 43.5× | 1.9× | +2% | 6.0% | |
| LFVNLifevantage | $73.5M | 14.7× | 19.4× | 0.4× | −20% | 2.8% | |
| CYHCommunity Health Systems | $296.2M | 8.1× | 4.5× | 0.0× | −8% | 0.3% | |
| Peer median | $208.9M | 15.3× | 20.5× | 2.1× | +6% | 4.8% |
More on Protara Therapeutics
Each number over time
Its groups
About
- Industry
- Biotechnology
- Sector
- Healthcare
Valuation data, not investment advice. Prices as of .